BI-1607
BioInvent expects a continued news-rich 2024
With a cash position of over one billion SEK, which provides significant operational flexibility, and with expected results from...
BioInvent and MSD to evaluate new treatment for metastatic melanoma
BioInvent, known for its innovative cancer immunotherapies, is expanding its...
BioInvent expects data from seven clinical studies in 2024
BioInvent entered 2024 with a solid...
BioInvent comments on progress in breast cancer study
BioInvent's pipeline consists of five drug candidates that are advancing...
BioInvent is charging for presentations of clinical data
BioInvent reached a milestone in the third quarter...
BioInvent reaches research milestone in collaboration with Exelixis
BioInvent has reached a research milestone in its collaboration...
BioInvent will soon have five drug candidates in six clinical studies
BioInvent has made a number of advances during the...
BioInvent's CFO on the company's business strategy
With a reported cash flow of just over 1,5 billion...
BioInvent reports clinical progress with BI-1206
A fourth complete response has been observed in phase...
BioInvent's CEO expects an eventful 2023
In 2022, the biotechnology company BioInvent demonstrated...
CMO provides insight into new BioInvent collaboration
From achieving a strong ownership base, a...
Regulatory success in the US for BioInvent
The US Food and Drug Administration (FDA) has approved BioInvent's Investigational...